VRS MD&A for Q ending June 30, 2012https://www.otciq.com/otciq/ajax/showFinancialReportById.pdf?id=89838.
There wasn't much, but of some interest might be the following titbits:
- At June 30, 2012, the Company held cash and short-term deposits of $3,542,305. Verisante expects these funds to be able to sustain operations until revenues are generated from sales of Aura™
- At June 30, 2012, the Company had cash and short term deposits of $3,542,305 as compared to cash and short term deposits of $5,871,402 at December 31, 2011.
- In connection with the Company’s increased operations and leasing of additional engineering and manufacturing space, rent increased by $18,132 in the three month period ending June 30 during 2012 over 2011.
- The Company paid $39,890 in royalties under the Licensing Agreement with the BC Cancer Agency during the six months ended June 30, 2012, compared to $76,932 in 2011. As the Company begins generating sales from Aura™ devices, it expects royalty payments increase significantly.